Oruka Therapeutics, Inc. (NASDAQ:ORKA) Receives Average Recommendation of “Buy” from Brokerages

Shares of Oruka Therapeutics, Inc. (NASDAQ:ORKA) have earned a consensus recommendation of “Buy” from the eight ratings firms that are covering the firm, Marketbeat Ratings reports. Seven equities research analysts have rated the stock with a buy recommendation and one has assigned a strong buy recommendation to the company. The average twelve-month price target among brokerages that have issued a report on the stock in the last year is $43.17.

A number of research analysts have weighed in on the company. TD Cowen assumed coverage on Oruka Therapeutics in a research note on Monday, September 16th. They issued a “buy” rating for the company. HC Wainwright reissued a “buy” rating and issued a $45.00 target price on shares of Oruka Therapeutics in a research note on Friday, December 20th. Leerink Partners initiated coverage on shares of Oruka Therapeutics in a research report on Tuesday, September 17th. They set an “outperform” rating and a $44.00 price target on the stock. Stifel Nicolaus started coverage on shares of Oruka Therapeutics in a research report on Friday, October 11th. They issued a “buy” rating and a $49.00 price objective for the company. Finally, Leerink Partnrs raised shares of Oruka Therapeutics to a “strong-buy” rating in a report on Tuesday, September 17th.

Institutional Investors Weigh In On Oruka Therapeutics

A number of large investors have recently modified their holdings of ORKA. Geode Capital Management LLC bought a new stake in shares of Oruka Therapeutics in the 3rd quarter worth approximately $343,000. The Manufacturers Life Insurance Company purchased a new position in Oruka Therapeutics during the third quarter valued at $1,037,000. Wellington Management Group LLP bought a new stake in Oruka Therapeutics in the third quarter worth $2,013,000. Janus Henderson Group PLC purchased a new stake in shares of Oruka Therapeutics in the third quarter worth $5,840,000. Finally, Redmile Group LLC purchased a new stake in shares of Oruka Therapeutics in the third quarter worth $10,091,000. Institutional investors own 56.44% of the company’s stock.

Oruka Therapeutics Price Performance

Oruka Therapeutics stock opened at $19.98 on Friday. The firm has a 50 day moving average of $24.13. Oruka Therapeutics has a twelve month low of $18.20 and a twelve month high of $53.88. The firm has a market capitalization of $699.28 million, a PE ratio of -3.19 and a beta of 0.78.

Oruka Therapeutics Company Profile

ARCA biopharma, Inc, a biopharmaceutical company, develops genetically-targeted therapies for heart failure and cardiovascular diseases. It is positioned to bring personalized therapies for the treatment of cardiovascular disease, through the use of genetics. Complementing the Company’s cardiovascular science, ARCA’s management team has significant experience in developing and commercializing cardiovascular products.